Greenwich LifeSciences, Inc. (GLSI) Stock Score, Valuation & Financial Research

Greenwich LifeSciences, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for GLSI

Greenwich LifeSciences, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 15.79. These figures are a research snapshot, not a buy or sell recommendation.

What Greenwich LifeSciences, Inc. does

Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase IIb clinical trials. This drug is designed to prevent the recurrence of breast cancer in patients who have already undergone surgical removal of the tumor. Founded in 2006 and based in Stafford, Texas, the company was formerly known as Norwell, Inc. until it rebranded to Greenwich LifeSciences, Inc. in March 2018.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company currently operates as a research and development entity and has not yet generated revenue from product sales, relying instead on capital raises to fund its clinical trials and operations.

Products and services

  • The company's primary product candidate is GP2, an immunotherapy designed to prevent breast cancer recurrence in patients who have previously undergone surgery.

Brands and product families

  • GP2 — The company's lead immunotherapy product candidate for breast cancer recurrence prevention. Source

Customer types

Breast cancer patients.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company utilizes third-party contract research organizations to manage and conduct its clinical trials. Source

Business relationships and partnerships

  • The Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF) — The company holds licensed rights from HJF to certain issued patents and pending patent applications related to GP2. Source

Business strengths to evaluate

  • Intellectual property portfolio covering GP2 in major global markets Source

Business risks and research considerations

  • Dependence on a single product candidate (GP2) Source
  • History of operating losses and need for additional capital Source
  • Clinical trial regulatory and execution risks Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

GLSI financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 15.79
Market capitalization:
231.77M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -21.68M
Free cash flow:
USD -9.91M
Cash:
USD 8.88M
Total debt:
USD 0.00
EPS:
USD -1.54

What stands out

  • Free cash flow is USD -9.91M, negative for the stored period.
  • The balance sheet shows USD 8.88M of cash versus USD 0.00 of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a missing revenue history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 8.88M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for GLSI

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can GLSI fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is GLSI likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for GLSI to reach sustainable profitability?
  • What does the current missing revenue history warning mean for the reliability or interpretation of GLSI's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research GLSI

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.